{"protocolSection":{"identificationModule":{"nctId":"NCT01235195","orgStudyIdInfo":{"id":"A0501097"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study Comparing the Drug Exposure in Humans After Administration of a 50 mg Tablet of Sertraline Hydrochloride as Compared to a 50 mg Capsule of Sertraline Hydrochloride Under Fasted (Nonfed) Conditions","officialTitle":"Phase 1, Open-Label, Randomized, Single-Dose, 2-Treatment, 2-Period Crossover Bioequivalence Study Comparing Sertraline Hydrochloride 50 mg Film-Coated Tablets To Sertraline Hydrochloride 50 mg Hard Capsules Under Fasted Conditions"},"statusModule":{"statusVerifiedDate":"2021-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-11"},"primaryCompletionDateStruct":{"date":"2010-12","type":"ACTUAL"},"completionDateStruct":{"date":"2010-12","type":"ACTUAL"},"studyFirstSubmitDate":"2010-11-03","studyFirstSubmitQcDate":"2010-11-03","studyFirstPostDateStruct":{"date":"2010-11-05","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-11-21","resultsFirstSubmitQcDate":"2012-04-10","resultsFirstPostDateStruct":{"date":"2012-05-07","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-01-25","lastUpdatePostDateStruct":{"date":"2021-01-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"This study is designed to determine differences in drug exposure in subjects after being administered 50 mg tablets of sertraline hydrochloride as compared to drug exposure after administering 50 mg capsules of sertraline hydrochloride under fasted (nonfed) conditions."},"conditionsModule":{"conditions":["Healthy"],"keywords":["bioequivalence study","sertraline 50 mg","capsules vs tablets"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"CROSSOVER","primaryPurpose":"BASIC_SCIENCE","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Sertraline 50 mg capsules","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sertraline hydrochloride"]},{"label":"Sertraline 50 mg tablet","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sertraline hydrochloride"]}],"interventions":[{"type":"DRUG","name":"sertraline hydrochloride","description":"50 mg capsule, single-dose","armGroupLabels":["Sertraline 50 mg capsules"],"otherNames":["Zoloft"]},{"type":"DRUG","name":"sertraline hydrochloride","description":"50 mg tablet, single-dose","armGroupLabels":["Sertraline 50 mg tablet"],"otherNames":["Zoloft"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Area Under the Curve From Time Zero to 72 Hours [AUC (0-72)]","description":"AUC (0-72)= Area under the plasma concentration versus time curve from time zero (pre-dose) to 72 hours (0-72).","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"},{"measure":"Maximum Observed Plasma Concentration (Cmax)","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"}],"secondaryOutcomes":[{"measure":"Time to Reach Maximum Observed Plasma Concentration (Tmax)","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"},{"measure":"Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]","description":"AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"},{"measure":"Residual Area Under the Concentration Time Curve [AUC(Res%)]","description":"AUC(res%) is the residual AUC defined as (AUCinf minus AUClast) divided by AUCinf. AUCinf is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. AUClast is the area under the plasma concentration-time curve from zero to the last measured concentration.","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"},{"measure":"Plasma Decay Half-Life (t1/2)","description":"Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).\n* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \\>45 kg (99 lbs).\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).\n* Any condition possibly affecting drug absorption (eg, gastrectomy)","healthyVolunteers":true,"sex":"ALL","minimumAge":"21 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Singapore","zip":"188770","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}}]},"referencesModule":{"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0501097&StudyName=A%20study%20comparing%20the%20drug%20exposure%20in%20humans%20after%20administration%20of%20a%2050%20mg%20tablet%20of%20sertraline%20hydrochloride%20as%20compared%20to%20a%20"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Sertraline 50 mg Capsule, Then Sertraline 50 mg Tablet","description":"Sertraline Hydrochloride 50 milligram (mg) hard gelatin capsule in the first intervention period, Sertraline Hydrochloride 50 mg Film-Coated Tablet in the second intervention period"},{"id":"FG001","title":"Sertraline 50 mg Tablet, Then Sertraline 50 mg Capsule","description":"Sertraline Hydrochloride 50 mg film-coated tablet in the first intervention period, Sertraline Hydrochloride 50 mg hard gelatin capsule in the second intervention period"}],"periods":[{"title":"First Intervention","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]},{"title":"Washout Period of At Least 8 Days","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]},{"title":"Second Intervention","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Entire Study Population","description":"Entire study population receiving Sertraline Hydrochloride 50 mg as either hard gelatin capsule or film-coated tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"30"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"30.4","spread":"8.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"23"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Area Under the Curve From Time Zero to 72 Hours [AUC (0-72)]","description":"AUC (0-72)= Area under the plasma concentration versus time curve from time zero (pre-dose) to 72 hours (0-72).","populationDescription":"All participants: all treated participants with at least one sertraline concentration were evaluated for pharmacokinetics.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram hour per milliliter (ng*h/mL)","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"419.9","spread":"147.14"},{"groupId":"OG001","value":"442.1","spread":"169.20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Natural log-transformed AUC (0-72) analyzed using a mixed effect model with sequence, period, treatment as fixed effects; subject within sequence as a random effect. Estimates of adjusted mean differences (Test minus Reference) and corresponding 90% confidence intervals (CIs) were obtained from the model. Adjusted mean differences and 90% CIs for differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test divided by Reference) and 90% CIs for the ratios.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of adjusted means","paramValue":"104.86","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"100.12","ciUpperLimit":"109.83","estimateComment":"Reference treatment=Sertraline hydrochloride 50 mg hard gelatin capsule. Test treatment=sertraline hydrochloride 50 mg film-coated tablet."}]},{"type":"PRIMARY","title":"Maximum Observed Plasma Concentration (Cmax)","populationDescription":"All participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanogram per milliliter (ng/mL)","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.96","spread":"5.0438"},{"groupId":"OG001","value":"19.03","spread":"6.3319"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Natural log-transformed Cmax analyzed using a mixed effect model with sequence, period, treatment as fixed effects; subject within sequence as a random effect. Estimates of adjusted mean differences (Test minus Reference) and corresponding 90% CIs were obtained from the model. Adjusted mean differences and 90% CIs for differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test divided by Reference) and 90% CIs for the ratios.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of adjusted means","paramValue":"105.34","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"98.46","ciUpperLimit":"112.69","estimateComment":"Reference treatment=Sertraline hydrochloride 50 mg hard gelatin capsule. Test treatment=sertraline hydrochloride 50 mg film-coated tablet."}]},{"type":"SECONDARY","title":"Time to Reach Maximum Observed Plasma Concentration (Tmax)","populationDescription":"All participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"3.00","upperLimit":"8.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"2.00","upperLimit":"8.00"}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]","description":"AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).","populationDescription":"All participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ng*h/mL","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"471.4","spread":"189.86"},{"groupId":"OG001","value":"493.8","spread":"204.90"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Natural log-transformed AUC (0-∞) analyzed using a mixed effect model with sequence, period, treatment as fixed effects; subject within sequence as a random effect. Estimates of adjusted mean differences (Test minus Reference) and corresponding 90% CIs were obtained from the model. Adjusted mean differences and 90% CIs for differences were exponentiated to provide estimates of the ratio of adjusted geometric means (Test divided by Reference) and 90% CIs for the ratios.","nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"Ratio (%) of adjusted means","paramValue":"106.1","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"100.16","ciUpperLimit":"112.39","estimateComment":"Reference treatment=Sertraline hydrochloride 50 mg hard gelatin capsule. Test treatment=sertraline hydrochloride 50 mg film-coated tablet."}]},{"type":"SECONDARY","title":"Residual Area Under the Concentration Time Curve [AUC(Res%)]","description":"AUC(res%) is the residual AUC defined as (AUCinf minus AUClast) divided by AUCinf. AUCinf is the area under the plasma concentration-time curve from time zero extrapolated to infinite time. AUClast is the area under the plasma concentration-time curve from zero to the last measured concentration.","populationDescription":"This parameter was not analyzed. It is reported individually for each subject and not analyzed statistically.","reportingStatus":"POSTED","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Plasma Decay Half-Life (t1/2)","description":"Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.","populationDescription":"All participants.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"hours","timeFrame":"Predose and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36, 48, and 72 hours postdose","groups":[{"id":"OG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule"},{"id":"OG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.45","spread":"3.9067"},{"groupId":"OG001","value":"25.40","spread":"3.3831"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","description":"The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one participant and as nonserious in another participant, or one participant may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Sertraline 50 mg Hard Gelatin Capsule","description":"All participants receiving Sertraline Hydrochloride 50 mg Hard Gelatin Capsule","seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":11,"otherNumAtRisk":30},{"id":"EG001","title":"Sertraline 50 mg Film-Coated Tablet","description":"All participants receiving Sertraline Hydrochloride 50 mg Film-Coated Tablet","seriousNumAffected":0,"seriousNumAtRisk":30,"otherNumAffected":13,"otherNumAtRisk":30}],"otherEvents":[{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":30},{"groupId":"EG001","numAffected":6,"numAtRisk":30}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":30}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":30}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30},{"groupId":"EG001","numAffected":2,"numAtRisk":30}]},{"term":"Catheter site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Catheter site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Musculoskeletal stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":3,"numAtRisk":30}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30},{"groupId":"EG001","numAffected":1,"numAtRisk":30}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":30}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30},{"groupId":"EG001","numAffected":0,"numAtRisk":30}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"interventionBrowseModule":{"meshes":[{"id":"D020280","term":"Sertraline"}],"ancestors":[{"id":"D015057","term":"1-Naphthylamine"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009281","term":"Naphthalenes"},{"id":"D011084","term":"Polycyclic Aromatic Hydrocarbons"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D011083","term":"Polycyclic Compounds"}]}},"hasResults":true}